<- Go Home
Connect Biopharma Holdings Limited
Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California.
Market Cap
$73.7M
Volume
240.1K
Cash and Equivalents
$27.0M
EBITDA
-$69.7M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$3.0M
Profit Margin
100.00%
52 Week High
$3.82
52 Week Low
$1.06
Dividend
N/A
Price / Book Value
2.74
Price / Earnings
-0.98
Price / Tangible Book Value
2.75
Enterprise Value
$42.8M
Enterprise Value / EBITDA
-0.62
Operating Income
-$70.4M
Return on Equity
140.51%
Return on Assets
-69.75
Cash and Short Term Investments
$31.5M
Debt
$596.0K
Equity
$26.9M
Revenue
$3.0M
Unlevered FCF
-$34.7M
Sector
Biotechnology
Category
N/A